LIVN: Growth is fueled by innovation, new product launches, and strong clinical and reimbursement tailwinds
Sustained double-digit growth is driven by talent, execution, and innovation, with new market entries and product launches in epilepsy and cardiopulmonary segments. Margin expansion will fund OSA investments, and strong clinical data and reimbursement improvements provide confidence in long-term ta…